What the labels name
Depo-Testosterone (testosterone cypionate) is for intramuscular use only and goes deep in the gluteal muscle.1 The Hikma enanthate label gives the same site, injected slowly and deeply, avoiding a blood vessel.2 Azmiro (cypionate) is a deep gluteal intramuscular injection only, with the prefilled syringe given by a healthcare professional.3
The Xyosted auto-injector label says to inject in the abdomen only, not within 2 inches of the belly button and not in any other area of the body.4 Its instructions say to use only the left or right side of the abdomen.4 No label in the pack names the thigh or the shoulder for intramuscular cypionate or enanthate.
Sites and routes people log for testosterone
Of the people logging testosterone cypionate, 84% logged the muscle route and 15% under the skin.15 For enanthate, 91% logged muscle and 9% under the skin.15 Among people logging enanthate, 39% logged a shoulder site and 25% a glute site, and 29% logged the left deltoid alone.15 For cypionate, 20% logged the left deltoid, 16% the right glute and 14% the left glute.15
Dorsogluteal and ventrogluteal sites
A review of gluteal intramuscular injections describes the ventrogluteal site as at the hip and the dorsogluteal site as the upper outer area of the gluteal muscles.5 A 2023 meta-analysis by Roldan-Chicano and colleagues of 1,429 participants from 17 studies linked ventrogluteal injections to lower pain in 9 studies, bleeding in 4 and hematoma in 2 than dorsogluteal ones, with no difference in reaching subcutaneous tissue.5 The dorsogluteal site is still the most widely used clinically and the ventrogluteal hardly used, so its real risks are hard to assess.5 A 2021 meta-analysis by Ayinde and colleagues (29 studies) reported that injections to the ventrogluteal site reduced pain compared with the dorsogluteal site in 2 studies, and also reported very high unexplained heterogeneity between studies overall.6
Under the skin or in the muscle
In a 2022 study by Choi and colleagues, 234 hypogonadal men were given intramuscular cypionate 100 mg weekly or the subcutaneous enanthate auto-injector 100 mg weekly, with levels taken at baseline and 12 weeks; the auto-injector was associated with lower estradiol and haematocrit, and sites were not compared.7 In a 2017 study by McFarland and colleagues, eleven female-to-male transgender patients already on weekly subcutaneous cypionate had no adverse effects; the Depo-Testosterone label names intramuscular use only.81
Lumps, site reactions and skin to avoid
Azmiro lists injection site reactions among its most common side effects: bruising, bleeding, redness and hardness.3 Among adverse reactions in the male that have occurred with some androgens, the Depo-Testosterone label lists inflammation and pain at the site of intramuscular injection.1 In a 26-week phase 3 study by Gittelman and colleagues (2019) of 133 men aged 18 to 75 on the auto-injector at 75 mg weekly, adjusted to 50 mg or 100 mg when indicated, injection-site haemorrhage was an adverse drug reaction in 6 men (4.5%) and bruising in 4 (3.0%), and mild pain was reported by 1 patient across 965 assessed injections.9 The Xyosted label lists injection site bruising among its most commonly reported adverse reactions.4
The Xyosted instructions say not to inject where the skin is tender, bruised, red, scaly or hard, or has scars or stretch marks.4 The labels and trials above list reactions but do not explain what causes a lump after an oil injection.
Syringe units for an oil dose
U-100 means 100 units of insulin in each millilitre, and a 1 mL syringe barrel holds up to 100 units.1011 Of the people logging testosterone cypionate, 37% set up 250 mg/mL, and 8% logged 125 mg at 50 units, which is 0.5 mL at 250 mg/mL.15
Frequently asked questions
Do testosterone labels say to rotate injection sites?
How long a needle for a gluteal or deltoid injection?
No testosterone label in the pack states a needle length or gauge. A 2023 review by Hemingway and colleagues of 14 studies of skin-to-muscle distance, covering intramuscular injections generally rather than testosterone, reported a correlation with obesity in all studies, and concludes that deltoid injections are more likely to achieve muscle penetration in both genders and in overweight or obese patients.14 The same review says needles longer than the standard 37 mm are recommended for all females at any gluteal site.14
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- Pharmacia & Upjohn (Pfizer) (via DailyMed). Depo-Testosterone (testosterone cypionate) injection, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- Hikma Pharmaceuticals USA (via DailyMed). Testosterone enanthate injection, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- Azurity Pharmaceuticals (via DailyMed). Azmiro (testosterone cypionate) injection, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- Antares Pharma (via DailyMed). Xyosted (testosterone enanthate) injection, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- Nursing Open (Roldan-Chicano et al.). Adverse effects of dorsogluteal versus ventrogluteal intramuscular injection: systematic review and meta-analysis. 2023. ebi.ac.uk
- PLoS One (Ayinde, Hayward, Ross). The effect of intramuscular injection technique on injection associated pain: systematic review and meta-analysis. 2021. ebi.ac.uk
- Journal of Urology (Choi et al.), PubMed abstract. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate (abstract). 2022. eutils.ncbi.nlm.nih.gov
- Journal of the Endocrine Society (McFarland et al.), PubMed abstract. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone (abstract). 2017. eutils.ncbi.nlm.nih.gov
- Journal of Sexual Medicine (Gittelman, Jaffe, Kaminetsky), PubMed abstract. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study (abstract). 2019. eutils.ncbi.nlm.nih.gov
- Eli Lilly and Company (via DailyMed). Humulin R (insulin human) U-100 injection, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- Embecta (maker of BD insulin syringes). Embecta diabetes care pharmacy catalog (BD Ultra-Fine and BD Veo insulin syringes). 2026. embecta.com
- Eli Lilly and Company (via DailyMed, US National Library of Medicine). Zepbound (tirzepatide) prescribing information and patient information, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- Novo Nordisk (via DailyMed). Ozempic (semaglutide) prescribing information and patient information, DailyMed. label as current 2026-11-17. dailymed.nlm.nih.gov
- British Journal of Nursing (Hemingway et al.), PubMed abstract. Considering skin-to-muscle depth for successful intramuscular injections in an increasingly obese population (abstract). 2023. eutils.ncbi.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted